Rocket Lab results match Wall Street estimates, company adds contracts for 10 launches

Rocket Lab results match Wall Street estimates, company adds contracts for 10 launches


Rocket Lab on Tuesday reported second-quarter results that largely met Wall Street’s expectations, and the company said it added contracts for 10 more launches in 2023 and 2024.

“The second quarter saw strong performance across Rocket Lab’s launch and space systems businesses with three successful Electron [rocket] launches, more than 17 spacecraft featuring Rocket Lab satellite components deployed to orbit, and multiple new launch contracts signed with new and returning customers,” Rocket Lab founder and CEO Peter Beck said in a statement.

The company reported a net loss of $45.9 million, or 10 cents per share, compared with a loss of 9 cents a share expected, according to analysts surveyed by Refinitiv. That was wider than the loss of 8 cents a share in the same quarter a year earlier.

Revenue grew 12% year over year in the second quarter to $62 million, versus $61.8 million expected by analysts surveyed by Refinitiv.

Rocket Lab’s launch business saw $22.5 million in revenue in the second quarter, while its space systems unit brought in $39.6 million. Its contract backlog increased from the previous quarter, rising by $40.1 million to $534.3 million.

Rocket Lab stock rose as much as 5% in after-hours trading from its close at $6.66 a share. The stock is the top performing pure-play space stock in 2023, up 77% year-to-date.

For the third quarter, Rocket Lab expects revenue to grow to between $73 million and $77 million.

Sign up here to receive weekly editions of CNBC’s Investing in Space newsletter.

The company said it passed “significant milestones” in the development of its coming Neutron rocket. Those developments included completing a second stage tank for the rocket, as well as finishing construction of a stand to conduct cryogenic tank tests – key for verifying the rocket’s design ahead of a first launch. Rocket Lab also expects to begin construction of Neutron’s launch site in Virginia in the third quarter.

Rocket Lab added orders for 10 launches of its Electron rocket since the end of the first quarter. Commercial satellite companies BlackSky and Synspective booked five and two Electron launches, respectively, while “a government customer” purchased two launches and “a confidential customer” ordered a “HASTE” mission. HASTE is a modified Electron rocket that flies hypersonic test missions, rather than carry satellites to orbit.

The launches are largely expected to happen in 2024.



Source

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push
Business

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push

U.S. Senator Elizabeth Warren (D-MA) and Director of the United States Office of Management and Budget, Russell Vought. Kevin Mohatt | Kevin Lamarque | | Reuters Sen. Elizabeth Warren on Friday accused the acting head of the Consumer Financial Protection Bureau of undermining President Donald Trump’s stated push to make credit cards more affordable, according […]

Read More
Why a niche category of CRE lending is suddenly seeing record deals
Business

Why a niche category of CRE lending is suddenly seeing record deals

Wepro | Moment | Getty Images A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight […]

Read More
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Business

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.  Top executives from drugmakers big and small told CNBC that the next phase […]

Read More